ArticleSchizophrenia (Heidelberg, Germany)2025
The electroencephalography protocol for the Accelerating Medicines Partnership® Schizophrenia Program: Reliability and stability of measures.
Abstract read
In one paragraph
Article in Schizophrenia (Heidelberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Visual P300 and Risk for Psychosis Onset in Youth at Clinical High Risk.Biological psychiatry · 2026Article
- Revolutionizing Pediatric Neurophysiology With Magnetoencephalography.Psychophysiology · 2026Review
- Body fluid biomarkers and psychosis risk in The Accelerating Medicines Partnership® Schizophrenia Program: design considerations.Schizophrenia (Heidelberg, Germany) · 2025Article
- Pathways to prevention: the Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ) Program.Schizophrenia (Heidelberg, Germany) · 2025Article
- Enabling FAIR data stewardship in complex international multi-site studies: Data Operations for the Accelerating Medicines Partnership® Schizophrenia Program.Schizophrenia (Heidelberg, Germany) · 2025Article
- Data analysis strategies for the Accelerating Medicines Partnership® Schizophrenia Program.Schizophrenia (Heidelberg, Germany) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
108 authors.
Daniel H MathalonDepartment of Psychiatry and Behavioral Sciences and Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA, USA. daniel.mathalon@ucsf.edu.ORCID http://orcid.org/0000-0001-6090-4974
Spero NicholasMental Health Service, Veterans Affairs San Francisco Health Care System, San Francisco, CA, USA.
Brian J RoachMental Health Service, Veterans Affairs San Francisco Health Care System, San Francisco, CA, USA.ORCID http://orcid.org/0000-0002-3264-1465
Tashrif BillahDepartment of Psychiatry, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Suzie LavoieOrygen, Parkville, VIC, Australia.ORCID http://orcid.org/0000-0001-8372-2399
Thomas WhitfordOrygen, Parkville, VIC, Australia.
Holly K HamiltonDepartment of Psychiatry and Behavioral Sciences and Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA, USA.ORCID http://orcid.org/0000-0002-4058-0949
Lauren AddamoOrygen, Parkville, VIC, Australia.
Andrey AnohkinWashington University School of Medicine, St. Louis, MO, USA.
Tristan BekinschteinConsciousness and Cognition Lab, Department of Psychology, University of Cambridge, Cambridge, UK.
Aysenil BelgerDepartment of Psychiatry, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.ORCID http://orcid.org/0000-0003-2687-1966
Kate BuccilliOrygen, Parkville, VIC, Australia.
John CahillDepartment of Psychiatry, Yale University School of Medicine, New Haven, CT, USA.
Ricardo E CarriónDepartment of Psychiatry, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, USA.ORCID http://orcid.org/0000-0002-6393-392X
Stefano DamianiDepartment of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy.ORCID http://orcid.org/0000-0002-5235-0788
Ilvana DzaficOrygen, Parkville, VIC, Australia.
Bjørn H EbdrupCentre for Neuropsychiatric Schizophrenia Research, CNSR Mental Health Centre, Glostrup, Denmark.
Igor IzyurovDepartment of Psychiatry and Psychotherapy, Jena University Hospital, Jena, Germany.
Johanna JarchoDepartment of Psychology & Neuroscience, Temple University, Philadelphia, PA, USA.
Raoul JenniCenter for Psychiatric Neuroscience, Department of Psychiatry, Lausanne University Hospital and University of Lausanne (CHUV-UNIL), Lausanne, Switzerland.ORCID http://orcid.org/0000-0001-6479-5381
Anna JoDepartment of Psychiatry, Chonnam National University Medical School, Gwangju, Korea.ORCID http://orcid.org/0000-0002-9820-5826
Sarah KerinsEarly Psychosis Detection and Clinical Intervention (EPIC) lab, Department of Psychosis Studies, King's College, London, UK.
Clarice LeeOrygen, Parkville, VIC, Australia.
Elizabeth A MartinDepartment of Psychological Science, University of California, Irvine, CA, USA.ORCID http://orcid.org/0000-0001-8893-1667
Rocio Mayol-TroncosoDepartment of Psychiatry, IMHAY, University of Chile, Santiago, Chile.ORCID http://orcid.org/0000-0002-6421-8768
Margaret A NiznikiewiczHarvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0003-3191-2005
Muhammad ParvazDepartment of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Oliver PogarellDepartment of Psychiatry and Psychotherapy, Ludwig Maximilian University of Munich, Munich, Germany.ORCID http://orcid.org/0000-0001-6455-4190
Julio Prieto-MontalvoDepartment of Child and Adolescent Psychiatry, Institute of Psychiatry and Mental Health, Hospital General Universitario Gregorio Marañón, IiSGM, CIBERSAM, Instituto de Salud Carlos III, School of Medicine, Universidad Complutense, Madrid, Spain.ORCID http://orcid.org/0000-0001-7711-0601
Rachel RabinPEPP-Montreal, Douglas Research Centre, Montreal, QC, Canada.ORCID http://orcid.org/0000-0002-6530-0288
David R RoalfDepartment of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Jack RogersInstitute for Mental Health, University of Birmingham, Birmingham, UK.
Dean F SalisburyDepartment of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Riaz ShaikDepartment of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Stewart ShankmanDepartment of Psychiatry and Behavioral Sciences, Northwestern University, Chicago, IL, USA.ORCID http://orcid.org/0000-0002-8097-4483
Michael C StevensDepartment of Psychiatry, Yale University School of Medicine, New Haven, CT, USA.
Yi Nam SuenSchool of Nursing, LKS Faculty of Medicine, University of Hong Kong, Hong Kong, China.
Nicole C SwannDepartment of Human Physiology, University of Oregon, Eugene, OR, USA.
Xiaochen TangShanghai Mental Health Center, Shanghai Jiaotong University School of Medicine, Shanghai, China.ORCID http://orcid.org/0000-0003-3796-7111
Judy L ThompsonDepartments of Psychiatry and Neuroscience, University of Rochester Medical Center, Rochester, NY, USA.
Ivy TsoDepartment of Psychiatry and Behavioral Health, Ohio State University Wexner Medical Center, Columbus, OH, USA.ORCID http://orcid.org/0000-0002-0984-1186
Julian WenzelDepartment of Psychiatry, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.ORCID http://orcid.org/0000-0002-3657-4263
Juan Helen ZhouCentre for Sleep and Cognition, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.ORCID http://orcid.org/0000-0002-0180-8648
Jean AddingtonDepartment of Psychiatry, Hotchkiss Brain Institute, University of Calgary, Calgary, AB, Canada.ORCID http://orcid.org/0000-0002-8298-0756
Luis AlamedaGeneral Psychiatry Service, Treatment and Early Intervention in Psychosis Program (TIPP-Lausanne), Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.ORCID http://orcid.org/0000-0002-8621-2885
Celso ArangoDepartment of Child and Adolescent Psychiatry, Institute of Psychiatry and Mental Health, Hospital General Universitario Gregorio Marañón, IiSGM, CIBERSAM, Instituto de Salud Carlos III, School of Medicine, Universidad Complutense, Madrid, Spain.ORCID http://orcid.org/0000-0003-3382-4754
Nicholas J K BreitbordeDepartment of Psychiatry and Behavioral Health, Ohio State University Wexner Medical Center, Columbus, OH, USA.
Matthew R BroomeInstitute for Mental Health, University of Birmingham, Birmingham, UK.ORCID http://orcid.org/0000-0002-6963-8884
Kristin S CadenheadDepartment of Psychiatry, University of California, San Diego, CA, USA.ORCID http://orcid.org/0000-0002-5952-4605
Monica E CalkinsDepartment of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Rolando I Castillo-PassiDepartment of Psychiatry, IMHAY, University of Chile, Santiago, Chile.ORCID http://orcid.org/0000-0002-9446-074X
Eric Yu Hai ChenDepartment of Psychiatry, School of Clinical Medicine, LKF Faculty of Medicine, University of Hong Kong, Hong Kong, China.ORCID http://orcid.org/0000-0002-5247-3593
Jimmy ChoiOlin Neuropsychiatry Research Center, Hartford HealthCare Behavioral Health Network, Hartford, CT, USA.
Philippe ConusGeneral Psychiatry Service, Treatment and Early Intervention in Psychosis Program (TIPP-Lausanne), Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Cheryl M CorcoranDepartment of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID http://orcid.org/0000-0002-8902-4353
Barbara A CornblattDepartment of Psychiatry, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, USA.
Covadonga M Diaz-CanejaDepartment of Child and Adolescent Psychiatry, Institute of Psychiatry and Mental Health, Hospital General Universitario Gregorio Marañón, IiSGM, CIBERSAM, Instituto de Salud Carlos III, School of Medicine, Universidad Complutense, Madrid, Spain.ORCID http://orcid.org/0000-0001-8538-3175
Lauren M EllmanDepartment of Psychology & Neuroscience, Temple University, Philadelphia, PA, USA.
Paolo Fusar-PoliDepartment of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy.
Pablo A GasparDepartment of Psychiatry, IMHAY, University of Chile, Santiago, Chile.ORCID http://orcid.org/0000-0002-9682-5327
Carla GerberPrevention Science Institute, University of Oregon, Eugene, OR, USA.
Louise Birkedal GlenthøjCopenhagen Research Centre for Mental Health, Mental Health Copenhagen, University of Copenhagen, Copenhagen, Denmark.
Leslie E HortonDepartment of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Christy Lai Ming HuiDepartment of Psychiatry, School of Clinical Medicine, LKF Faculty of Medicine, University of Hong Kong, Hong Kong, China.
Joseph KambeitzDepartment of Psychiatry, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.ORCID http://orcid.org/0000-0002-8988-3959
Lana Kambeitz-IlankovicDepartment of Psychiatry and Psychotherapy, Ludwig Maximilian University of Munich, Munich, Germany.
Matcheri S KeshavanDepartment of Psychiatry, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA.
Minah KimDepartment of Neuropsychiatry, Seoul National University Hospital, Seoul, Korea.ORCID http://orcid.org/0000-0001-8668-0817
Sung-Wan KimDepartment of Psychiatry, Chonnam National University Medical School, Gwangju, Korea.ORCID http://orcid.org/0000-0002-6739-2163
Nikolaos KoutsoulerisDepartment of Psychiatry and Psychotherapy, Ludwig Maximilian University of Munich, Munich, Germany.ORCID http://orcid.org/0000-0001-6825-6262
Jun Soo KwonDepartment of Psychiatry, Hanyang University Hospital, Seoul, South Korea.ORCID http://orcid.org/0000-0002-1060-1462
Kerstin LangbeinDepartment of Psychiatry and Psychotherapy, Jena University Hospital, Jena, Germany.
Daniel MamahDepartment of Psychiatry, Washington University Medical School, St. Louis, MO, USA.
Vijay A MittalDepartment of Psychology, Northwestern University, Evanston, IL, USA.ORCID http://orcid.org/0000-0001-9017-5119
Merete NordentoftDepartment of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
Godfrey D PearlsonDepartment of Psychiatry, Yale University School of Medicine, New Haven, CT, USA.
Jesus PerezCAMEO, Early Intervention in Psychosis Service, Cambridgeshire and Peterborough NHS Foundation Trust, Cambridge, UK.
Diana O PerkinsDepartment of Psychiatry, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.ORCID http://orcid.org/0000-0001-9396-2206
Albert R PowersDepartment of Psychiatry, Yale University School of Medicine, New Haven, CT, USA.ORCID http://orcid.org/0000-0003-3057-5043
Fred W SabbPrevention Science Institute, University of Oregon, Eugene, OR, USA.
Jason SchiffmanDepartment of Psychological Science, University of California, Irvine, CA, USA.
Jai L ShahDepartment of Psychiatry, McGill University, Montreal, QC, Canada.ORCID http://orcid.org/0000-0002-7549-6990
Steven M SilversteinDepartments of Psychiatry and Neuroscience, University of Rochester Medical Center, Rochester, NY, USA.ORCID http://orcid.org/0000-0002-0699-0960
Stefan SmesnyDepartment of Psychiatry and Psychotherapy, Jena University Hospital, Jena, Germany.
William S StoneDepartment of Psychiatry, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0003-2932-7288
Gregory P StraussDepartment of Psychology, University of Georgia, Athens, GA, USA.
Rachel UpthegroveInstitute for Mental Health, University of Birmingham, Birmingham, UK.ORCID http://orcid.org/0000-0001-8204-5103
Swapna K VermaInstitute of Mental Health, Singapore, Singapore.
Jijun WangShanghai Mental Health Center, Shanghai Jiaotong University School of Medicine, Shanghai, China.ORCID http://orcid.org/0000-0001-5427-7425
Daniel H WolfDepartment of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.ORCID http://orcid.org/0000-0002-9731-8781
Tianhong ZhangShanghai Mental Health Center, Shanghai Jiaotong University School of Medicine, Shanghai, China.ORCID http://orcid.org/0000-0002-5379-7119
Sylvain BouixDepartment of Software Engineering and Information Technology, École de technologie supérieure, Montreal, QC, Canada.ORCID http://orcid.org/0000-0003-1326-6054
Ofer PasternakDepartment of Psychiatry, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Kang-Ik K ChoDepartment of Psychiatry, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0001-7135-3848
Michael J ColemanDepartment of Psychiatry, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Dominic DwyerOrygen, Parkville, VIC, Australia.ORCID http://orcid.org/0000-0003-3949-5867
Angela NunezDepartment of Psychiatry, Yale University School of Medicine, New Haven, CT, USA.
Zailyn TamayoDepartment of Psychiatry, Yale University School of Medicine, New Haven, CT, USA.
Stephen J WoodOrygen, Parkville, VIC, Australia.ORCID http://orcid.org/0000-0003-4186-5919
Rene S KahnDepartment of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID http://orcid.org/0000-0001-5909-8004
John M KaneDepartment of Psychiatry, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, USA.
Patrick D McGorryOrygen, Parkville, VIC, Australia.
Carrie E BeardenDepartment of Psychological Science, University of California, Irvine, CA, USA.ORCID http://orcid.org/0000-0002-8516-923X
Barnaby NelsonOrygen, Parkville, VIC, Australia.
Scott W WoodsDepartment of Psychiatry, Yale University School of Medicine, New Haven, CT, USA.ORCID http://orcid.org/0000-0002-3103-5228
Martha E ShentonDepartment of Psychiatry, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0003-4235-7879
Accelerating Medicines Partnership® Schizophrenia Program
Gregory A LightDepartment of Psychiatry, University of California, San Diego, CA, USA.
Funding
ProNET: Psychosis-Risk Outcomes NetworkU01MH124639 · NIMH · YALE UNIVERSITY · PI CARRIE E BEARDEN, JOHN M KANE · 2020 to 2026
$81.2MPsychosis Risk Evaluation, Data Integration and Computational Technologies (PREDICT): Data Processing, Analysis, and Coordination CenterU24MH124629 · NIMH · BRIGHAM AND WOMEN'S HOSPITAL · PI Rene S. Kahn, Martha E. Shenton · 2020 to 2026
$32.6MTrajectories and Predictors in the Clinical High Risk for Psychosis Population: Prediction Scientific Global Consortium (PRESCIENT)U01MH124631 · NIMH · UNIVERSITY OF MELBOURNE · PI Christopher Barnaby Nelson · 2020 to 2026
$30.4MNIMH NIH HHS U01 MH124631NIMH NIH HHS U01 MH124639NIMH NIH HHS U24 MH124629U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (NIMH) U01MH124639U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (NIMH) U24MH124629Wellcome TrustWellcome Trust (Wellcome) 220664/Z/20/Z
Abstract
Individuals at clinical high risk for psychosis (CHR) have variable clinical outcomes and low conversion rates, limiting development of novel and personalized treatments. Moreover, given risks of antipsychotic drugs, safer effective medications for CHR individuals are needed. The Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ) Program was launched to address this need. Based on past CHR and schizophrenia studies, AMP SCZ assessed electroencephalography (EEG)-based event-related potential (ERP), event-related oscillation (ERO), and resting EEG power spectral density (PSD) measures, including mismatch negativity (MMN), auditory and visual P300 to target (P3b) and novel (P3a) stimuli, 40-Hz auditory steady state response, and resting EEG PSD for traditional frequency bands (eyes open/closed). Here, in an interim analysis of AMP SCZ EEG measures, we assess test-retest reliability and stability over sessions (baseline, month-2 follow-up) in CHR (n = 654) and community control (CON; n = 87) participants. Reliability was calculated as Generalizability (G)-coefficients, and changes over session were assessed with paired t-tests. G-coefficients were generally good to excellent in both groups (CHR: mean = 0.72, range = 0.49-0.85; CON: mean = 0.71, range = 0.44-0.89). Measure magnitudes significantly (p < 0.001) decreased over session (MMN, auditory and visual target P3b, visual novel P3a, 40-Hz ASSR) and/or over runs within sessions (MMN, auditory/visual novel P3a and target P3b), consistent with habituation effects. Despite these small systematic habituation effects, test-retest reliabilities of the AMP SCZ EEG-based measures are sufficiently strong to support their use in CHR studies as potential predictors of clinical outcomes, markers of illness progression, and/or target engagement or secondary outcome measures in controlled clinical trials.
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.